MAP2K1 and melanoma: Combination therapies, such as Encorafenib (LGX818) with Binimetinib (MEK162), demonstrate long-term efficacy in patients with advanced BRAF V600 mutated melanoma, by blocking the mutated BRAF kinase protein and MEK1/2, respectively [40].